论文部分内容阅读
目的:探讨复方苦参注射液持续滴注联合肝动脉化疗栓塞(TACE)治疗中晚期原发性肝癌的临床疗效。方法:选择不宜手术的中晚期肝癌患者40例,随机分为治疗组和对照组各20例,均采用TACE治疗。治疗组在术后第2天行外周中心静脉置管(PICC),连接化疗泵,每天持续24小时静脉滴注复方苦参注射液。结果:2组均无显著缓解病例,治疗组无变化例数较对照组高,但差异无显著性意义(P>0.05)。在疼痛缓解疗效方面,治疗组比对照组具有较高的缓解率,差异有显著性意义(P<0.05)。在腹胀缓解疗效方面,治疗组较对照组具有较高的缓解率,差异有显著性意义(P<0.05)。治疗组Karnofsky(KPS)评分显著提高,与治疗前比较,差异有非常显著性意义(P<0.01),对照组也有提高,但与治疗前比较,差异无显著性意义(P>0.05)。2组治疗后比较,差异有显著性意义(P<0.05)。2组在血常规、肝肾功能等方面未见明显毒副反应。结论:复方苦参注射液静脉持续滴注联合TCAE治疗中晚期原发性肝癌疗效显著,能改善患者症状和生活质量,为中西医结合治疗肝癌提供了一条新的途径。
Objective: To investigate the curative effect of compound Kushen injection continuous infusion combined with transcatheter arterial chemoembolization (TACE) in the treatment of advanced primary liver cancer. Methods: Forty patients with advanced hepatocellular carcinoma who were unfit for surgery were randomly divided into treatment group (n = 20) and control group (n = 20), all treated with TACE. The treatment group received peripheral central venous catheterization (PICC) on the second postoperative day, and the chemotherapy pump was connected. The compound Kushen injection was administered intravenously for 24 hours a day. Results: No significant relief was found in both groups. No change was found in the treatment group compared with the control group, but the difference was not statistically significant (P> 0.05). In the pain relief efficacy, the treatment group than the control group has a high response rate, the difference was significant (P <0.05). In the treatment of abdominal distension, the treatment group had a higher response rate than the control group, with significant difference (P <0.05). The score of Karnofsky (KPS) in the treatment group was significantly higher than that before treatment, the difference was significant (P <0.01), and the control group also increased. However, the difference was not significant (P> 0.05). There was significant difference between the two groups after treatment (P <0.05). 2 groups in the blood, liver and kidney function and so no obvious side effects. Conclusion: Compound Kushen injection continuous intravenous infusion combined with TCAE in the treatment of advanced primary liver cancer has a significant effect, can improve the symptoms and quality of life in patients with traditional Chinese and western medicine for the treatment of liver cancer provides a new way.